Regeneron Gains Exclusive Access to 300 Million Patient Records Through TriNetX Collaboration

Partnership will expand Regeneron's genomic and proteomic database to drive drug discovery and digital health solutions

Apr. 2, 2026 at 9:00pm

Got story updates? Submit your updates here. ›

An extreme close-up macro X-ray photograph revealing the intricate internal structures of a human genome or protein molecule in glowing, ghostly detail against a dark background, conceptually representing the power of combining large-scale genomic and real-world health data.Regeneron's partnership with TriNetX will expand its world-leading genomic and proteomic database, unlocking new possibilities for drug discovery and digital health innovation.Cambridge Today

Regeneron Pharmaceuticals has entered into a strategic collaboration with TriNetX, a global health data network, to gain exclusive access to de-identified electronic health records of approximately 300 million patients. This will allow Regeneron to dramatically expand its world-leading genomic and proteomic database, a key driver of the company's drug discovery and development pipeline. The partnership will also empower Regeneron's efforts to create innovative digital health solutions for consumers, patients, and providers.

Why it matters

This collaboration represents a major milestone for Regeneron's Genetics Center, which has spent over a decade building one of the world's largest databases linking genomic and proteomic data to longitudinal health records. Combining TriNetX's extensive network of real-world data with Regeneron's advanced analytics and AI capabilities will accelerate the discovery and development of new medicines, as well as the creation of transformative digital health tools.

The details

Under the agreement, TriNetX will provide Regeneron with secure, licensed access to its current and future de-identified health data from around 300 million individuals globally. Regeneron will have the ability to match a portion of this data to the genomic and proteomic information generated by its Regeneron Genetics Center. This will dramatically expand Regeneron's already world-leading dataset, which the company uses to drive its industry-leading therapeutics pipeline and pioneering work in genetic medicine and digital health.

  • Regeneron and TriNetX announced the collaboration on April 2, 2026.
  • Regeneron will invest up to $200 million in TriNetX as part of the agreement.

The players

TriNetX

A global health data network that provides secure access to de-identified patient records from its network of over 11,000 healthcare provider locations.

Regeneron Pharmaceuticals

A leading biotechnology company that invents, develops, and commercializes life-transforming medicines, with a focus on areas like eye diseases, cancer, and genetic conditions.

Regeneron Genetics Center

A genomic research initiative and wholly owned subsidiary of Regeneron that has built one of the world's largest databases linking genomic and proteomic data to longitudinal health records.

Got photos? Submit your photos here. ›

What they’re saying

“We are delighted to work with Regeneron, and specifically the Regeneron Genetics Center team, to advance human health through the application of intelligence-driven information technology, powered by our trusted data.”

— Jeff Margolis, TriNetX Executive Chairman

“This is a major milestone for the RGC and a powerful new pathway to achieve our core mission: building the world's largest and richest human health database to drive drug development and pioneer digital health solutions for consumers, patients and providers.”

— Aris Baras, M.D., Senior Vice President, Head of RGC and Co-head of Regeneron Genetic Medicines

What’s next

Regeneron will invest up to $200 million in TriNetX as part of the collaboration, which will enable the companies to further expand their combined data and analytics capabilities.

The takeaway

This partnership represents a significant step forward in Regeneron's efforts to leverage large-scale genomic, proteomic, and real-world data to accelerate the discovery and development of innovative medicines, as well as create transformative digital health solutions that could improve outcomes for patients and providers.